Veradermics Stock Jumps After VDPHL01 Hair-Loss Pill Hits Trial Goals
Veradermics shares rose 40% Monday after its oral hair-loss drug VDPHL01 met all main goals in a Phase 2/3 trial of 519 men. Patients taking the drug saw average hair count increases of 30.3 to 33.0 hairs per square centimeter over six months, compared to 7.3 for placebo. No treatment-related serious or heart-related adverse events were reported.